The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 1 will cover pediatric liver disease, liver transplantation, and portal hypertension.

Hepatologists are often consulted by our oncology colleagues when patients develop immune-mediated liver injury from checkpoint Inhibitors (ILICI) that are steroid refractory and resistant. Speakers in this session discuss the exploratory second-line and third-line treatment options that have been succesfully used in case series, case reports, and in other immune-mediated adverse events such as colitis, pneumonitis, dermatitis, and myocarditis.

In an era of rapid change and uncertainty, the ability to adapt and excel is crucial for early career investigators seeking sustained success. This community conversation focuses on strategies for maintaining productivity, resilience, and innovation amid evolving professional and personal landscapes. Panelists provide actionable insights to help attendees navigate uncertainty, embrace change, manage stress and burnout, and drive meaningful progress in their work when faced with setbacks or barriers. 

Experts examine the importance of fibrosis staging in the risk assessment and management of metabolic-associated steatohepatitis (MASH). The session explores the clinical implications of focusing on early-stage versus late-stage fibrosis; evaluates the role of advanced diagnostic tools in stratifying risk; and reviews how targeted approaches can improve patient outcomes. This community conversation aims to impart a deeper understanding of how to prioritize interventions based on fibrosis severity and emerging evidence.

This meet-up fosters meaningful interaction between the patient community with health care clinicians focused on those affected by primary biliary cholangitis (PBC).

Join the experts in this session to learn about highly relevant, clinical hot topic issues for hepatitis B management in 2025. Topics include: quantitative HBsAg testing in clinical practice; HCC risk calculators; noninvasive testing for hepatic fibrosis; and metabolic dysfunction-associated steatotic liver disease in patients with HBV infection. 

Cell stress can lead to proliferative arrest (senescence), which can accelerate disease progression through a variety of mechanisms. Subject matter experts explore triggers and pathways that convert cells to a senescent, secretory phenotype.&nbsp;Session topics include: characteristics of cell senescence; the role of cellular senescence in the progression of chronic liver injury; types of cell populations affected (hepatocytes, cholangiocytes, hepatic stellate cells, and others); beneficial and harmful effects of cell senescence; molecular mechanisms; and potential therapeutic strategies.&nbsp;<br />
<br />
&nbsp;

Explore the transformative role of artificial intelligence (AI) in pediatric hepatology and liver transplantation, highlighting how AI innovations are reshaping early diagnosis, risk stratification, and personalized treatment strategies for pediatric liver diseases. Experts review AI-driven advancements in noninvasive diagnostics, predictive analytics for disease progression, and optimizing donor-recipient matching in liver transplantation. Speakers also address the role of AI in improving posttransplant care, including graft survival prediction and early detection of complications. Emphasizing practical applications, ongoing challenges, and ethical considerations, this session demonstrates how AI can enhance decision-making, improve outcomes, and pave the way for precision medicine in pediatric liver care.

Presenters explore commonly encountered clinical scenarios where practice patterns are variable and consensus is often lacking on the appropriate application of guidelines. Experts offer insights from real-world experience and large-scale data to generate consensus on the best clinical practices in the following scenarios: applying portal hypertension guidance to individual patients; improving surgical risk stratification; rethinking spontaneous bacterial peritonitis prophylaxis; and optimizing use of albumin and terlipressin.

Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.<br />
<br />
&nbsp;